[CAS NO. 525-79-1] Kinetin
PRODUCTS SPECIFICATIONS [525-79-1]
DESCRIPTION [525-79-1]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 215.21 |
| Molecular Formula | C10H9N5O |
| SMILES | C12=NC=NC(NCC3=CC=CO3)=C1N=CN2 |
2 Publications Citing Use of MCE
Summary
Kinetin (N6-furfuryladenine) belongs to the family of N6-substituted adenine derivatives known as cytokinins, which are plant hormones involved in cell division, differentiation and other physiological processes. Kinetin has anti-aging effects [1] .
In Vitro
Kinetin (N6-furfuryladenine) shows to have a direct effect on superoxide dismutase activity in plants; prevent oxidation of unsaturated acids in plant membranes; slow down development and aging in insects, by reducing their fecundity and increasing the specific activity of catalase; and delay the onset of many age-related characteristics that appear in normal human skin fibroblasts undergoing aging in vitro. Kinetin (70-150 μM) markedly suppressed hydroxyl radical formation by about 41% and 76%, respectively
[1]
.
The plant cytokinin kinetin dramatically increases exon 20 inclusion in RNA isolated from cultured familial dysautonomia (FD) cells
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Kinetin (N6-furfuryladenine) (2-6 mg/kg; injection into the tail vein) effectively prevents ADP-induced acute pulmonary thrombosis in mice
[1]
.
Subjects received 23.5 mg/kg/d for 28 d. An increase in WT IKBKAP mRNA expression in leukocytes was noted after 8 d in six of eight individuals; after 28 d, the mean increase compared with baseline was significant
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | ADP-induced acute pulmonary thrombosis 20-24 g mice (ICR strain) [1] |
| Dosage: | 2, 4, 6 mg/kg |
| Administration: | Injection into the tail vein |
| Result: | Reduced mortality to 70%, 40% and 35% at 2, 4, and 6 mg/kg, respectively. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02274051 | NYU Langone Health |
Familial Dysautonomia
|
November 2009 | Phase 1 |
Appearance
Solid
Source
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 33.33 mg/mL ( 154.87 mM ; Need ultrasonic)
H 2 O : 1 mg/mL ( 4.65 mM ; ultrasonic and warming and heat to 80°C)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 4.6466 mL | 23.2331 mL | 46.4662 mL |
| 5 mM | 0.9293 mL | 4.6466 mL | 9.2932 mL |
| 10 mM | 0.4647 mL | 2.3233 mL | 4.6466 mL |
References
- [1] Hsiao G, et al. Inhibitory activity of kinetin on free radical formation of activated platelets in vitro and on thrombus formation in vivo. Eur J Pharmacol. 2003 Apr 4;465(3):281-7.
- [2] Hims MM, et al. Therapeutic potential and mechanism of kinetin as a treatment for the human splicing disease familial dysautonomia. J Mol Med (Berl). 2007 Feb;85(2):149-61.
- [3] Axelrod FB, et al. Kinetin improves IKBKAP mRNA splicing in patients with familial dysautonomia. Pediatr Res. 2011 Nov;70(5):480-3.
- [4] Griffaut B, et al. Cytotoxic effects of kinetin riboside on mouse, human and plant tumour cells. Int J Biol Macromol. 2004 Aug;34(4):271-5.
Synonyms
